Unnamed: 0,title,date,stock,sentiment
330147.0,Cytokinetics and The ALS Association Renew Partnership to Advance the Fight Against ALS,2020-05-27 08:37:00-04:00,CYTK,negative
330148.0,"The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces $1.34B Common Stock Offering",2020-05-19 08:24:00-04:00,CYTK,positive
330149.0,"The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter",2020-05-13 07:40:00-04:00,CYTK,neutral
330150.0,Stocks That Hit 52-Week Highs On Tuesday,2020-05-12 10:41:00-04:00,CYTK,neutral
330151.0,"The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands $384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings",2020-05-12 08:06:00-04:00,CYTK,negative
330152.0,"Morgan Stanley Maintains Overweight on Cytokinetics, Raises Price Target to $29",2020-05-12 08:04:00-04:00,CYTK,negative
330153.0,78 Biggest Movers From Yesterday,2020-05-12 05:02:00-04:00,CYTK,neutral
330154.0,Mid-Afternoon Market Update: NASDAQ Rises Over 100 Points; Amneal Pharmaceuticals Shares Surge On Upbeat Results,2020-05-11 15:02:00-04:00,CYTK,positive
330155.0,54 Stocks Moving In Monday's Mid-Day Session,2020-05-11 12:39:00-04:00,CYTK,neutral
330156.0,Stocks That Hit 52-Week Highs On Monday,2020-05-11 10:28:00-04:00,CYTK,neutral
330157.0,FDA Grants Amgen And Cytokinetics Fast Track Designation For Omecamtiv Mecarbil In Heart Failure,2020-05-08 08:31:00-04:00,CYTK,negative
330158.0,Cytokinetics Q1 EPS $(0.660) Misses $(0.500) Estimate,2020-05-06 16:00:00-04:00,CYTK,negative
330159.0,"The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle",2020-05-06 08:42:00-04:00,CYTK,positive
330160.0,"Benzinga's Top Upgrades, Downgrades For May 5, 2020",2020-05-05 09:35:00-04:00,CYTK,positive
330161.0,"Mizuho Initiates Coverage On Cytokinetics with Buy Rating, Announces Price Target to $31",2020-05-05 06:23:00-04:00,CYTK,neutral
330162.0,The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace,2020-05-03 08:45:00-04:00,CYTK,neutral
330163.0,"Cytokinetics And Astellas Pharma Inc. Entered Two Agreements, Which Amend And Restate Co's Research, Development Commercialization Collaboration",2020-04-23 16:24:00-04:00,CYTK,positive
330164.0,10 Biggest Price Target Changes For Friday,2020-04-17 08:14:00-04:00,CYTK,neutral
330165.0,"Cantor Fitzgerald Reiterates Overweight on Cytokinetics, Raises Price Target to $23",2020-04-17 07:40:00-04:00,CYTK,negative
330166.0,Cytokinetics Says Believes It Is On Track To Achieve Its Key Strategic Objectives For 2020,2020-04-14 07:32:00-04:00,CYTK,neutral
330167.0,"Benzinga's Top Upgrades, Downgrades For April 9, 2020",2020-04-09 10:02:00-04:00,CYTK,positive
330168.0,10 Biggest Price Target Changes For Thursday,2020-04-09 08:13:00-04:00,CYTK,neutral
330169.0,Cytokinetics shares are trading higher after Morgan Stanley upgraded the company's stock from Equal-Weight to Overweight and raised its price target from $14 to $25.,2020-04-09 07:12:00-04:00,CYTK,negative
330170.0,"Morgan Stanley Upgrades Cytokinetics to Overweight, Raises Price Target to $25",2020-04-09 06:08:00-04:00,CYTK,negative
330171.0,Cytokinetics Q1 EPS $(0.04) Down From $0.15 YoY,2020-03-30 08:18:00-04:00,CYTK,neutral
330172.0,"Shares of several healthcare companies are trading higher following Senate passage of a $2 trillion economic stimulus package, which has lifted stocks across sectors.",2020-03-26 11:49:00-04:00,CYTK,positive
330173.0,Cytokinetics Granted European Orphan Designation For Reldesemtiv For The Treatment Of Amyotrophic Lateral Sclerosis,2020-03-04 07:38:00-05:00,CYTK,positive
330174.0,Cytokinetics Sees FY20 Cash Revenues $18M-$22M,2020-03-03 16:01:00-05:00,CYTK,neutral
330175.0,"Cytokinetics Q4 EPS $(0.52) Misses $(0.44) Estimate, Sales $5.2M Miss $7.19M Estimate",2020-03-03 16:00:00-05:00,CYTK,negative
330176.0,"The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More",2020-03-03 07:51:00-05:00,CYTK,positive
330177.0,"The Week Ahead In Biotech: COVID-19 Stocks In The Spotlight, Earnings Taper Off",2020-02-29 14:52:00-05:00,CYTK,neutral
330178.0,"Amgen, Cytokinetics, Servier Report Continuation Of GALACTIC-HF Following Interim Analysis",2020-02-26 08:32:00-05:00,CYTK,neutral
330179.0,"The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA",2020-02-19 07:21:00-05:00,CYTK,negative
330180.0,"The Daily Biotech Pulse: Epizyme's Tazemetostat sNDA Accepted For Priority Review, Eisai To Withdraw Weight Loss Drug, Sol-Gel Prices Offering",2020-02-14 08:23:00-05:00,CYTK,negative
330181.0,Stocks That Hit 52-Week Highs On Thursday,2020-02-13 10:26:00-05:00,CYTK,neutral
330182.0,"The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO",2020-02-13 08:05:00-05:00,CYTK,negative
330183.0,Stocks That Hit 52-Week Highs On Wednesday,2020-02-12 11:45:00-05:00,CYTK,neutral
330184.0,"The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data",2020-02-12 09:18:00-05:00,CYTK,positive
330185.0,Stocks That Hit 52-Week Highs On Tuesday,2020-02-11 10:17:00-05:00,CYTK,neutral
330186.0,"Cytokinetics Announces Publication Relating to Design of GALACTIC-HF, a Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure",2020-02-06 04:59:00-05:00,CYTK,negative
330187.0,"Cytokinetics Announces Start of Redwood-HCM, a Phase 2 Clinical Trial of CK-3773274",2020-01-06 07:38:00-05:00,CYTK,neutral
330188.0,"Cytokinetics Director Henderson Buys 6,000 @$8.57",2020-01-02 14:26:00-05:00,CYTK,neutral
330189.0,Cytokinetics Granted FDA Orphan Drug Designation For Reldesemtiv For Treatment Of Amyotrophic Lateral Sclerosis,2019-12-18 07:34:00-05:00,CYTK,positive
330190.0,58 Biggest Movers From Friday,2019-12-16 05:49:00-05:00,CYTK,neutral
330191.0,"The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission",2019-12-05 07:14:00-05:00,CYTK,positive
330192.0,"The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More",2019-12-01 09:30:00-05:00,CYTK,neutral
330193.0,77 Biggest Movers From Yesterday,2019-11-20 04:57:00-05:00,CYTK,neutral
330194.0,Cytokinetics Highlights Will Present Added Results From COSMIC-HF Phase 2 Trial At American Heart Association Scientific Sessions 2019,2019-11-11 09:06:00-05:00,CYTK,neutral
330195.0,94 Biggest Movers From Yesterday,2019-11-08 06:01:00-05:00,CYTK,neutral
330196.0,75 Stocks Moving In Thursday's Mid-Day Session,2019-11-07 12:19:00-05:00,CYTK,neutral
330197.0,Cytokinetics Q3 EPS $(0.5) Down From $(0.4) YoY,2019-10-31 16:01:00-04:00,CYTK,neutral
330198.0,Cytokinetics Highlights Presentation Of Added Analyses From FORTITUDE-ALS At NEALS Meeting,2019-10-04 07:31:00-04:00,CYTK,neutral
330199.0,50 Biggest Movers From Yesterday,2019-09-27 04:31:00-04:00,CYTK,neutral
330200.0,Cytokinetics To Present Additional Results From FORTITUDE-ALS At 18th Annual NEALS Meeting Oct.13,2019-09-26 16:00:00-04:00,CYTK,neutral
330201.0,Cytokinetics Highlights Data From Phase 1 Study Of CK-3773274 At HFSA Meeting,2019-09-16 07:44:00-04:00,CYTK,neutral
330202.0,84 Biggest Movers From Yesterday,2019-09-10 05:01:00-04:00,CYTK,neutral
330203.0,"The Week Ahead In Biotech: Conference Presentations, IPO News Flow Take The Spotlight",2019-09-08 11:01:00-04:00,CYTK,neutral
330204.0,Stocks That Hit 52-Week Highs On Friday,2019-09-06 12:23:00-04:00,CYTK,neutral
330205.0,10 Biggest Price Target Changes For Friday,2019-09-06 09:07:00-04:00,CYTK,neutral
330206.0,"Cantor Fitzgerald Reiterates Overweight on Cytokinetics, Raises Price Target to $20",2019-09-06 07:53:00-04:00,CYTK,negative
330207.0,A List Of Stocks Reaching New 52-Week Highs,2019-08-09 10:29:00-04:00,CYTK,positive
330208.0,"Cytokinetics Q2 EPS $(0.56) Misses $(0.5) Estimate, Sales $7.137M Beat $6.99M Estimate; Results From Phase 1 Study Of Ck-274 To Be Presented At Hfsa In September 2019; Phase 2 Clinical Trial Expected To Begin In Q4",2019-08-08 16:38:00-04:00,CYTK,negative
330209.0,Stocks That Set New 52-Week Highs Thursday,2019-08-08 12:19:00-04:00,CYTK,neutral
330210.0,"The Daily Biotech Pulse: Glaukos To Buy Avedro, Mixed Adcom Vote For Gilead, Dynavax Offering",2019-08-08 07:11:00-04:00,CYTK,neutral
330211.0,Stocks That Managed To Breach 52-Week Highs Wednesday Morning,2019-08-07 10:16:00-04:00,CYTK,neutral
330212.0,"The Daily Biotech Pulse: Novartis Stands By Zolgensma, GW Pharma Q2 Propelled By Epidiolex Sales, Ionis-Akcea Clinical Readout",2019-08-07 07:34:00-04:00,CYTK,neutral
330213.0,Stocks That Managed to Breach 52-Week Highs Wednesday Morning,2019-07-31 11:01:00-04:00,CYTK,neutral
330214.0,Cytokinetics Reports Preclinical Data For CK-3773274 Presented At American Heart Association's Basic Cardiovascular Sciences Scientific Sessions,2019-07-31 07:44:00-04:00,CYTK,neutral
330215.0,Companies That Achieved 52-Week Highs Friday,2019-07-26 15:37:00-04:00,CYTK,neutral
330216.0,Cytokinetics Highlights Publication Of Preclinical Data Showing Fast Skeletal Muscle Troponin Activator Improves Muscle Energetics,2019-07-24 07:35:00-04:00,CYTK,positive
330217.0,Cytokinetics Reports Was Granted European Orphan Designation For Reldesemtiv For Treatment Of Spinal Muscular Atrophy,2019-07-23 07:44:00-04:00,CYTK,positive
330218.0,Cytokinetics Highlights Presentation Of Preclinical Data Related To CK-3773274 At American Heart Association's Basic Cardiovascular Sciences Scientific Sessions,2019-07-22 16:00:00-04:00,CYTK,neutral
330219.0,"Cytokinetics Announces Completion Of Enrollment In GALACTIC-HF, Phase 3 Clinical Trial Of Omecamtiv Mecarbil In Patients With Heart Failure",2019-07-15 07:34:00-04:00,CYTK,negative
330220.0,Cytokinetics Reports Preclinical Data For Reldesemtiv Was Presented At 2019 Annual Cure SMA Conference,2019-06-28 07:34:00-04:00,CYTK,neutral
330221.0,"Cytokinetics Reports Will Present Preclinical Data For Reldesemtiv At SMA Conference Jun. 28, 29",2019-06-24 16:01:00-04:00,CYTK,neutral
330222.0,60 Biggest Movers From Yesterday,2019-06-18 04:54:00-04:00,CYTK,neutral
330223.0,50 Biggest Movers From Friday,2019-05-28 05:01:00-04:00,CYTK,neutral
330224.0,30 Stocks Moving In Friday's Mid-Day Session,2019-05-24 13:00:00-04:00,CYTK,neutral
330225.0,Cytokinetics shares are trading higher after the company reported better-than-expected Q1 sales results.,2019-05-10 10:18:00-04:00,CYTK,positive
330226.0,"Cytokinetics Q1 EPS $(0.54) Misses $(0.47) Estimate, Sales $8.464M Beat $6.86M Estimate",2019-05-09 16:01:00-04:00,CYTK,negative
330227.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Mon., May 6, 2019",2019-05-06 11:49:00-04:00,CYTK,positive
330228.0,26 Stocks Moving In Monday's Pre-Market Session,2019-05-06 08:07:00-04:00,CYTK,neutral
330229.0,"Cytokinetics Announces FORTITUDE-ALS, a Phase 2 Clinical Trial of Reldesemtiv in Patients With ALS Did Not Meet Statistical Significance for Primary Efficacy Analysis",2019-05-05 17:39:00-04:00,CYTK,negative
330230.0,"The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs",2019-05-04 16:56:00-04:00,CYTK,neutral
330231.0,Cytokinetics Option Alert: May 17 $9 Calls at the Ask: 1406 @ $1.101 vs 1461 OI; Earnings 5/7 After Close [est] Ref=$9.29,2019-04-29 14:15:00-04:00,CYTK,positive
330232.0,Cytokinetics Option Alert: May 17 $10 Calls at the Ask: 1200 @ $0.35 vs 72 OI; Earnings 4/25 After Close [est] Ref=$8.05,2019-04-01 11:46:00-04:00,CYTK,positive
330233.0,60 Biggest Movers From Yesterday,2019-03-22 05:36:00-04:00,CYTK,neutral
330234.0,"The Daily Biotech Pulse: Biogen Plummets, FDA Greenlights Sleep Disorder Drug, Cellular Biomedicine Offering",2019-03-21 07:51:00-04:00,CYTK,negative
330235.0,52 Biggest Movers From Yesterday,2019-03-21 04:59:00-04:00,CYTK,neutral
330236.0,41 Stocks Moving In Wednesday's Mid-Day Session,2019-03-20 12:00:00-04:00,CYTK,neutral
330237.0,Cytokinetics shares are trading higher after the Data Monitoring Committee for the company's GALACTIC-HF recommended Cytokinetics' phase 3 trial continue without changes.,2019-03-20 09:06:00-04:00,CYTK,positive
330238.0,"Amgen, Cytokinetics, Servier Report Continuation Of GALACTIC-HF Following Planned Interim Analysis",2019-03-20 08:31:00-04:00,CYTK,neutral
330239.0,Cytokinetics To Present Additional Results From COSMIC-HF At American College of Cardiology's 68th Annual Scientific Session,2019-03-18 16:00:00-04:00,CYTK,neutral
330240.0,Cytokinetics To Present Additional Results From COSMIC-HF At American College of Cardiology's 68th Annual Scientific Session,2019-03-11 16:39:00-04:00,CYTK,neutral
330241.0,Cytokinetics Highlights Presentation Of Results From FORTITUDE-ALS At American Academy Of Neurology 71st Annual Meeting,2019-03-07 16:12:00-05:00,CYTK,neutral
330242.0,"Cytokinetics Entered Sales Agreement Through Which Co May Offer, Sell Common Stock Of Up to $35M Through Cantor Fitzgerald",2019-03-07 06:13:00-05:00,CYTK,positive
330243.0,"Cytokinetics Q4 EPS $(0.48) Beats $(0.52) Estimate, Sales $9.377M Beat $3.94M Estimate",2019-02-21 16:01:00-05:00,CYTK,neutral
330244.0,"Amgen, Cytokinetics Report METEORIC-HF Second Phase 3 Trial Of Omecamtiv Mecarbil Is Open For Enrollment",2019-02-21 08:35:00-05:00,CYTK,neutral
330245.0,"The Daily Biotech Pulse: Genomic Health Earnings, AbbVie's Humira Approved For Another Indication In Japan",2019-02-21 07:32:00-05:00,CYTK,positive
330246.0,"Cytokinetics Announces Initiation Of Phase 1 Clinical Study Of AMG 594, A Cardiac Troponin Activator",2019-02-20 09:02:00-05:00,CYTK,neutral
330247.0,Cytokinetics Says it is Preparing to Conduct an Additional Phase 1 Study of Reldesemtiv,2019-01-22 07:35:00-05:00,CYTK,neutral
330248.0,"Cytokinetics Announces Initiation of Phase 1 Clinical Trial of CK-3773274, a Cardiac Myosin Inhibitor",2018-12-05 07:33:00-05:00,CYTK,negative
330249.0,"Jim Cramer Gives His Opinion On Netflix, Kraft Heinz And More",2018-12-03 07:57:00-05:00,CYTK,neutral
330250.0,"Cytokinetics Completes Enrollment In FORTITUDE-ALS, Phase 2 Clinical Trial Of Reldesemtiv In Patients With ALS; Clinical Trial Results Expected In First Half Of 2019",2018-11-27 07:30:00-05:00,CYTK,neutral
330251.0,"The Daily Biotech Pulse: FDA Nod For Mallinckrodt's Pain Drug, AbbVie-Neurocrine Report Positive Elagolix Results",2018-11-15 08:10:00-05:00,CYTK,positive
330252.0,"Cytokinetics Q3 EPS $(0.40) Beats $(0.51) Estimate, Sales $10.64M Beat $3.15M Estimate",2018-11-01 16:01:00-04:00,CYTK,neutral
330253.0,"The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal",2018-11-01 07:30:00-04:00,CYTK,negative
330254.0,48 Biggest Movers From Yesterday,2018-10-17 05:53:00-04:00,CYTK,neutral
330255.0,Cytokinetics Unveils Expanded Development Pipeline And Provides Key Updates On Late-Stage Clinical Research Programs At R&D Day,2018-10-16 07:35:00-04:00,CYTK,neutral
330256.0,"The Week Ahead In Biotech: Conferences, Clinical Trial Results And IPOs",2018-10-08 07:30:00-04:00,CYTK,neutral
330257.0,"Cytokinetics, Astellas Offer Update Related To Collaborative Skeletal Muscle Program",2018-10-05 07:36:00-04:00,CYTK,neutral
330258.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-09-23 16:10:00-04:00,CYTK,neutral
330259.0,Cantor Fitzgerald's 7 Buys For 7 Biotechs,2018-09-21 15:32:00-04:00,CYTK,neutral
330260.0,"Cantor Fitzgerald Initiates Coverage On Cytokinetics with Overweight Rating, Announces $14 Price Target",2018-09-21 08:44:00-04:00,CYTK,negative
330261.0,"The Week Ahead In Biotech (Sept. 16-22): Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-09-16 14:22:00-04:00,CYTK,neutral
330262.0,"Morgan Stanley Assumes Cytokinetics at Equal-Weight, Announces Price Target $10",2018-09-10 07:28:00-04:00,CYTK,neutral
330263.0,"Stocks Which Set New 52-Week Low Yesterday, August 1st",2018-08-02 11:07:00-04:00,CYTK,negative
330264.0,10 Biggest Price Target Changes For Wednesday,2018-08-01 09:51:00-04:00,CYTK,neutral
330265.0,Cytokinetics Downgraded On Data Delay,2018-08-01 09:39:00-04:00,CYTK,negative
330266.0,"Benzinga's Top Upgrades, Downgrades For August 1, 2018",2018-08-01 09:08:00-04:00,CYTK,positive
330267.0,"Morgan Stanley Downgrades Cytokinetics to Equal-Weight, Lowers Price Target to $9",2018-08-01 07:20:00-04:00,CYTK,negative
330268.0,"Cytokinetics Q2 EPS $(0.51), Inline, Sales $6.2M Beat $5.19M Estimate",2018-07-26 16:01:00-04:00,CYTK,neutral
330269.0,"Benzinga's Daily Biotech Pulse: Biogen, AC Immune Slip Despite Positive Trials, Sarepta Slapped With Clinical Hold",2018-07-26 08:40:00-04:00,CYTK,negative
330270.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs",2018-07-22 17:03:00-04:00,CYTK,neutral
330271.0,60 Biggest Movers From Yesterday,2018-06-19 04:02:00-04:00,CYTK,neutral
330272.0,Mid-Afternoon Market Update: Crude Oil Up Over 1%; Gevo Shares Spike Higher,2018-06-18 14:38:00-04:00,CYTK,negative
330273.0,'$CYTK -15% on some really mediocre SMA data presented over the weekend. Squint hard and you might see some benefit in ambulatory Type III patients but the bar is so much higher these days.'-STAT's Adam Feuerstein Tweets,2018-06-18 12:54:00-04:00,CYTK,positive
330274.0,42 Stocks Moving In Monday's Mid-Day Session,2018-06-18 12:28:00-04:00,CYTK,neutral
330275.0,Mid-Day Market Update: Verastem Shares Climb On Duvelisib Data; ZIOPHARM Oncology Shares Slide,2018-06-18 12:16:00-04:00,CYTK,positive
330276.0,Mid-Morning Market Update: Markets Open Lower; Vintage Capital To Acquire Rent-A-Center For $15/Share,2018-06-18 10:18:00-04:00,CYTK,negative
330277.0,Cytokinetics Announces Data  From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy Presented at 2018 Annual Cure SMA Conference,2018-06-16 15:13:00-04:00,CYTK,neutral
330278.0,"Cytokinetics Announces Data From Phase 2 Clinical Study Of Reldesemtiv In Patients With Spinal Muscular Atrophy Will Be Presented At 2018 Annual Cure SMA Conference On June 16, 2018",2018-06-08 16:01:00-04:00,CYTK,neutral
330279.0,"Cytokinetics, Cure SMA Report Renewal, Expanded Partnership To Advance Education, Awareness Of SMA",2018-05-17 07:34:00-04:00,CYTK,neutral
330280.0,"Benzinga's Daily Biotech Pulse: Intra-cellular Moves On Poster Presentation, Earnings Beats From Vertex, Exact Sciences",2018-04-27 07:25:00-04:00,CYTK,neutral
330281.0,"Cytokinetics Q1 EPS $(0.56) Misses $(0.51) Est., Sales $5.27M Misses $6.58M Est.",2018-04-26 16:16:00-04:00,CYTK,negative
330282.0,Cytokinetics On Phase 2 Study Of Reldesemtiv In Patients With Spinal Muscular Atrophy: Enrollment Stopped Short Of Targeted 72 Patients After Blinded Analyses Of Variability Showed Study Has Sufficient Statistical Power To Detect Relevant Differences,2018-04-24 07:42:00-04:00,CYTK,negative
330283.0,"Cytokinetics Reports Q4 EPS $(0.75) vs $(0.70) Est., Sales $6.2M vs $6.3M Est.",2018-02-15 16:00:00-05:00,CYTK,neutral
330284.0,Cytokinetics Earnings Outlook,2018-02-15 09:29:00-05:00,CYTK,neutral
330285.0,A Peek Into The Markets: U.S. Stock Futures Signal Higher Start On Wall Street,2017-12-11 07:17:00-05:00,CYTK,neutral
330286.0,"5 Stocks To Watch For December 11, 2017",2017-12-11 05:19:00-05:00,CYTK,neutral
330287.0,"Cytokinetics Reports VITALITY-ALS Did Not Meet Primary, Secondary Endpoints In Phase 3 Trial Of Tirasemtiv",2017-12-08 16:56:00-05:00,CYTK,neutral
330288.0,"New Publication Summarizes Phase 1 Studies of CK-2127107 Showing Tolerability, Amplification of Skeletal Muscle Response to Nerve Activation",2017-11-30 07:31:00-05:00,CYTK,neutral
330289.0,36 Biggest Movers From Yesterday,2017-11-30 05:09:00-05:00,CYTK,neutral
330290.0,33 Stocks Moving In Wednesday's Mid-Day Session,2017-11-29 12:28:00-05:00,CYTK,neutral
330291.0,35 Stocks Moving In Wednesday's Pre-Market Session,2017-11-29 08:04:00-05:00,CYTK,neutral
330292.0,Seeing Notable Block Trade In Cytokinetics of 1.3M Shares At $8/Share,2017-11-24 09:53:00-05:00,CYTK,negative
330293.0,"Benzinga's Top Upgrades, Downgrades For November 22, 2017",2017-11-22 09:10:00-05:00,CYTK,positive
330294.0,Cantor Fitzgerald Downgrades Cytokinetics to Neutral,2017-11-22 07:18:00-05:00,CYTK,neutral
330295.0,40 Biggest Movers From Yesterday,2017-11-22 05:03:00-05:00,CYTK,neutral
330296.0,Mid-Afternoon Market Update: Dow Gains 180 Points; DSW Shares Drop On Earnings Miss,2017-11-21 14:35:00-05:00,CYTK,positive
330297.0,Hearing Needham Downgrades Cytokinetics From Strong Buy to Buy,2017-11-21 13:34:00-05:00,CYTK,positive
330298.0,40 Stocks Moving In Tuesday's Mid-Day Session,2017-11-21 12:42:00-05:00,CYTK,neutral
330299.0,Mid-Day Market Update: Signet Jewelers Falls After Q3 Results; Cheetah Mobile Shares Surge,2017-11-21 12:20:00-05:00,CYTK,positive
330300.0,Mid-Morning Market Update: Markets Open Higher; Lowe's Tops Q3 Expectations,2017-11-21 10:32:00-05:00,CYTK,positive
330301.0,Why Is Cytokinetics Plunging Today?,2017-11-21 09:47:00-05:00,CYTK,neutral
330302.0,33 Stocks Moving In Tuesday's Pre-Market Session,2017-11-21 08:08:00-05:00,CYTK,neutral
330303.0,Cytokinetics Shares To Resume Trade At 8 a.m. EST,2017-11-21 07:47:00-05:00,CYTK,positive
330304.0,"Cytokinetics Reports Phase 3 Clinical Trial of Tirasemtiv in Patients with ALS 
Did Not Meet Primary or Secondary Endpoints",2017-11-21 07:30:00-05:00,CYTK,neutral
330305.0,"Cytokinetics Halted, News Pending",2017-11-21 07:28:00-05:00,CYTK,neutral
330306.0,"Cytokinetics Q3 EPS $(0.60) vs $(0.62) Est., Sales $6.18M vs $6.47M Est.",2017-10-26 16:01:00-04:00,CYTK,neutral
330307.0,"Seaport Global Initiates Coverage On Cytokinetics with Buy Rating, Announces $24.00 Price Target",2017-10-06 09:56:00-04:00,CYTK,neutral
330308.0,"UPDATE: Cytokinetics Says ‍ Coincident With Patient Dosing In Galactic-HF, Amgen Will Make $10M Milestone Payment to Cytokinetics​",2017-09-19 07:37:00-04:00,CYTK,neutral
330309.0,"Cytokinetics Reports Dosing of Initial Patient in Japan in GALACTIC-HF, Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure",2017-09-19 07:32:00-04:00,CYTK,negative
330310.0,"Secondary Offering Lockups To Expire Today Include: Aeglea BioTherapeutics, Exact Sciences, Evolent Health, and Cytokinetics",2017-08-07 08:26:00-04:00,CYTK,neutral
330311.0,"Cytokinetics Reports Q2 EPS $(0.60) vs $(0.57) Est., Sales $3.1M vs $8.22M Est.",2017-08-02 16:23:00-04:00,CYTK,neutral
330312.0,Cytokinetics Reports Results From Phase 2 Trial Of Omecamtiv Mecarbil In Japense Patients With Heart Failure; Co. Eligible To Earn $10M Milestone Payment From Amgen Upon First Patient Dosing In Phase 3 Trial,2017-08-02 07:42:00-04:00,CYTK,negative
330313.0,Cytokinetics Announces Start of Phase 2 Clinical Trial FORTITUDE-ALS,2017-07-27 07:41:00-04:00,CYTK,neutral
330314.0,Cytokinetics Reports Baseline Data From First Cohort of Phase 2 Clinical Trial of CK-2127107 in Patients With SMA,2017-07-05 07:31:00-04:00,CYTK,neutral
330315.0,Cytokinetics Reports Initiation of Phase 1b Clinical Trial of CK-2127107 in Elderly Subjects With Limited Mobility,2017-06-29 07:32:00-04:00,CYTK,negative
330316.0,Cytokinetics Announces Orphan Drug Desigination for CK-2127107,2017-05-15 07:34:00-04:00,CYTK,neutral
330317.0,Cytokinetics Granted FDA Orphan Status for Fast Skeletal Muscle Troponin Activator,2017-05-12 07:45:00-04:00,CYTK,positive
330318.0,20 Biggest Mid-Day Losers For Tuesday,2017-05-09 12:32:00-04:00,CYTK,negative
330319.0,25 Stocks Moving In Tuesday's Pre-Market Session,2017-05-09 08:16:00-04:00,CYTK,neutral
330320.0,Cytokinetics Prices 5.26M Share Offering @$14.25/Share,2017-05-09 04:10:00-04:00,CYTK,positive
330321.0,Cytokinetics Reports Offering of $75M in Shares,2017-05-08 16:30:00-04:00,CYTK,positive
330322.0,"Cytokinetics Reports Q1 EPS $(0.62) vs $(0.27) Est., Sales $4.2M",2017-04-27 18:22:00-04:00,CYTK,neutral
330323.0,Cytokinetics Added to S&P SmallCap 600,2017-04-21 16:00:00-04:00,CYTK,neutral
330324.0,12 Biggest Mid-Day Gainers For Tuesday,2017-04-18 12:39:00-04:00,CYTK,neutral
330325.0,25 Stocks Moving In Tuesday's Pre-Market Session,2017-04-18 08:35:00-04:00,CYTK,neutral
330326.0,Cytokinetics Reports Starts of Second Cohort in Phase 2 Trial of CK-2127107 in Patients with Spinal Muscular Atrophy,2017-03-29 07:32:00-04:00,CYTK,neutral
330327.0,Cytokinetics Still A Buy After Phase 2 SMA Data,2017-03-23 08:46:00-04:00,CYTK,neutral
330328.0,"Traders Circulating New Bullish Report on Cytokinetics from SmithOnStocks: 'Cytokinetics: A Look at the Clinical Trial Programs Underway (CYTK, Buy, $13.00)'",2017-03-15 10:49:00-04:00,CYTK,neutral
330329.0,18 Biggest Mid-Day Gainers For Wednesday,2017-03-08 12:58:00-05:00,CYTK,neutral
330330.0,"Benzinga's Top Upgrades, Downgrades For March 8, 2017",2017-03-08 09:23:00-05:00,CYTK,positive
330331.0,"Rodman & Renshaw Initiates Coverage On Cytokinetics With Buy, Announces $25 Price Target",2017-03-08 07:01:00-05:00,CYTK,neutral
330332.0,Cytokinetics Announces Add'l Results From COSMIC-HF Pase 2 Trial To Be Presented At Annual Scientific Session Mar. 18,2017-03-06 16:01:00-05:00,CYTK,neutral
330333.0,"Cytokinetics Reports Q4 Net Income $0.18 Does Not Compare To $(0.27), Rev. $33.1M Does Not Compare To $16.33M Est.",2017-02-16 16:01:00-05:00,CYTK,neutral
330334.0,"Benzinga's Top Upgrades, Downgrades For February 6, 2017",2017-02-06 09:40:00-05:00,CYTK,positive
330335.0,Needham Upgrades Cytokinetics To Strong Buy,2017-02-06 08:11:00-05:00,CYTK,positive
330336.0,"Cytokinetics, Royalty Pharma Announce $100 Million Transaction for Omecamtiv Mecarbil; Royalty Buys 4.5% Royalty On Worldwide Sales For $90M, Plus $10M Equity In Cytokinetics",2017-02-02 07:34:00-05:00,CYTK,neutral
330337.0,6 Stocks Analysts Forecast The Largest Year-Over-Year Revenue Declines,2016-12-27 08:14:00-05:00,CYTK,neutral
330338.0,Cytokinetics Pops to High of $12.15 on Volume Following CNBC Mention,2016-12-16 14:36:00-05:00,CYTK,neutral
330339.0,Cytokinetics Announces New Data Presented at the International Symposium on ALS/MND,2016-12-09 07:31:00-05:00,CYTK,neutral
330340.0,Origent Data Sciences and Cytokinetics Present Analyses Demonstrating Baseline Data Predict Measures of Vital Capacity in Patients With ALS,2016-12-07 07:32:00-05:00,CYTK,positive
330341.0,"Cytokinetics Announces Start of GALACTIC-HF, a Phase 3 Clinical Trial of Omecamtiv Mecarbil; Earns $26.7M Milestone Payment From Amgen",2016-12-01 07:30:00-05:00,CYTK,neutral
330342.0,20 Biggest Mid-Day Gainers For Friday,2016-10-28 12:24:00-04:00,CYTK,neutral
330343.0,"Cytokinetics Reports Q3 EPS $0.80 Does Not Compare To $(0.29), Rev. $59M",2016-10-27 16:37:00-04:00,CYTK,neutral
330344.0,Cytokinetics Reports First Patient Has Been Enrolled in VIGOR-ALS,2016-10-18 07:32:00-04:00,CYTK,neutral
330345.0,"Cytokinetics Reports Early Termination of HSR Waiting Period for Expanded Collaboration with Astellas; Upfront Payment of $65M from Astellas Due, Payable Within 30 Days",2016-09-29 07:38:00-04:00,CYTK,neutral
330346.0,Cytokinetics Reports Triggering of Milestone Payment from Astellas Related to Next-Gen Fast Skeletal Muscle Activator Entering IND-Enabling Studies,2016-09-08 07:31:00-04:00,CYTK,neutral
330347.0,12 Biggest Mid-Day Losers For Thursday,2016-09-01 14:51:00-04:00,CYTK,negative
330348.0,"Cytokinetics, Amgen to Advance Omecamtiv Mecarbil to Phase 3 Clinical Development",2016-09-01 08:33:00-04:00,CYTK,neutral
330349.0,"Cytokinetics Reports Q2 EPS (0.29) vs. Est. $(0.31), Rev. $5.8M vs. Est. $10.15M",2016-07-28 16:24:00-04:00,CYTK,neutral
330350.0,"Needham Maintains Buy on Cytokinetics, Raises PT to $17.00, Says Amgen Decision to Move Omecamtiv to Phase III May Be An Upcoming Driver Of Upside",2016-07-27 12:04:00-04:00,CYTK,neutral
330351.0,Cytokinetics And Astellas Announce Option Right For Tirasemtiv And Expansion Of Global Collaboration For CK-2127107 In ALS,2016-07-27 07:39:00-04:00,CYTK,neutral
330352.0,Cytokinetics Reports Start of Phase 2 Clinical Trial of CK-2127107 in Patients With Chronic Obstructive Pulmonary Disease,2016-06-30 07:30:00-04:00,CYTK,neutral
330353.0,"Cytokinetics Reports Q1 EPS $(0.31) vs. Est. $(0.34), Rev. $8.4M vs. Est. $7.38M",2016-04-28 16:08:00-04:00,CYTK,neutral
330354.0,Cytokinetics Reports Commencement of Phase 2 Trial of Omecamtiv Mecarbil in Japanese Subjects with Heart Failure,2016-04-04 07:31:00-04:00,CYTK,negative
330355.0,Why Does The Street Like Small-Caps Cytokinetics And Anavex?,2016-02-18 15:35:00-05:00,CYTK,positive
330356.0,Cytokinetics Sees FY16 Cash Sales $13M-$16M,2016-02-16 16:02:00-05:00,CYTK,neutral
330357.0,"Cytokinetics Reports Q4 EPS $(0.24) vs $(0.32) Est., Sales $9.8M vs $10.5M Est.",2016-02-16 16:00:00-05:00,CYTK,neutral
330358.0,Cytokinetics Presents Exploratory Analyses of Data from Phase 3 Clinical Trial of Dexpramipexole in Patients with ALS,2016-01-10 18:29:00-05:00,CYTK,neutral
330359.0,"Roth Capital Positive On Cytokinetics, Says Patnerships And Regulatory Visibility Generates Compelling Investment Opportunity",2016-01-04 10:21:00-05:00,CYTK,positive
330360.0,Cytokinetics Reports Initiation of Phase 2 Clinical Trial of CK-2127107 in Patients With Spinal Muscular Atrophy,2016-01-04 07:30:00-05:00,CYTK,neutral
330361.0,"Cytokinetics Shares Up 6.5% On The Morning; Earlier News Of Cure SMA, Cytokinetics Collaboration To Increase Funding & Awareness For Spinal Muscular Atrophy",2015-12-08 10:29:00-05:00,CYTK,positive
330362.0,Cytokinetic Shares Falling,2015-12-03 13:54:00-05:00,CYTK,positive
330363.0,"Amgen, Cytokinetics Announce Late-Breaking Presentation of COSMIC-HF Trial at AHA Scientific Sessions 2015",2015-11-08 16:46:00-05:00,CYTK,neutral
330364.0,Mid-Afternoon Market Update: Dow Surges 150 Points; Lendingtree Shares Slide,2015-11-02 15:00:00-05:00,CYTK,positive
330365.0,Mid-Day Market Update: Dyax Jumps On Acquisition News; Endurance International Shares Dip,2015-11-02 12:17:00-05:00,CYTK,positive
330366.0,Cytokinetics Sees FY15 Rev. $44-$47M vs. Est. $32.98M,2015-10-29 16:27:00-04:00,CYTK,neutral
330367.0,"Cytokinetics Reports Q3 EPS $(0.23) vs. Est. $(0.30), Rev. $7.9M vs. Est. $11.24M",2015-10-29 16:26:00-04:00,CYTK,neutral
330368.0,"Amgen and Cytokinetics Announce Positive Top-Line Results From COSMIC-HF, A Phase 2 Trial of Omecamtiv Mecarbil in Patients With Chronic Heart Failure",2015-10-27 08:01:00-04:00,CYTK,positive
330369.0,"8-K from Cytokinetics Shows Entered Loan, Security Deal with Oxford Finance, Silicon Valley Bank for $40M in Series of Term Loans, $15M Borrowing from Lenders",2015-10-19 17:22:00-04:00,CYTK,positive
330370.0,"Cytokinetics Reports Q2 Loss of $0.27/Share vs Loss of $0.24/Share Est., Sales $6.5M vs $7M Est.; Sees Sales $44M-$47M",2015-07-29 16:46:00-04:00,CYTK,negative
330371.0,"Cowen & Company Initiates Coverage on Cytokinetics at Outperform, Announces $9.00 PT",2015-07-15 09:10:00-04:00,CYTK,neutral
330372.0,Mid-Day Market Update: Vince Holding Declines After CEO Resignation; Natural Health Trends Shares Surge,2015-07-14 12:49:00-04:00,CYTK,positive
330373.0,Mid-Morning Market Update: Markets Rise; JPMorgan Earnings Beat Views,2015-07-14 10:21:00-04:00,CYTK,neutral
330374.0,Cytokinetics Reports Initiating Phase 3 Clinical Trial of Tirasemtiv in Patients With ALS,2015-07-14 07:43:00-04:00,CYTK,neutral
330375.0,"Cytokinetics, ALS Association Announce Awarding of Grant for Phase 3 Clinical Trial and Biomarker Research Partnership",2015-07-14 07:34:00-04:00,CYTK,positive
330376.0,Cytokinetics Shows Results Of Phase I Studies of CK-2127107,2015-06-19 07:30:00-04:00,CYTK,neutral
330377.0,"Cytokinetics Director Gage Buys 10,000 Shares @$5.71/Share -Form 4",2015-05-08 15:54:00-04:00,CYTK,positive
330379.0,Cytokinetics Announces Publication of Preclinical Data Relating to CK-2127107 and Exercise Tolerance in Rodent Model of Heart Failure,2015-02-26 04:35:00-05:00,CYTK,negative
330380.0,Morning Market Gainers,2015-02-13 09:45:00-05:00,CYTK,neutral
330381.0,Piper Jaffray Upgrades Cytokinetics to Overweight,2015-02-13 06:32:00-05:00,CYTK,negative
330382.0,FDA Approves Cytori U.S. Pivotal Scleroderma Trial,2015-01-12 08:03:00-05:00,CYTK,positive
330383.0,Mid-Afternoon Market Update: U.S. Stocks Turn Red; Tekmira Pharmaceuticals Shares Climb Following Clinical Study Update,2014-12-31 14:17:00-05:00,CYTK,positive
330384.0,Mid-Day Gainers From New Year's Eve 2014: NephroGenex And Other Biopharma Stocks,2014-12-31 12:42:00-05:00,CYTK,neutral
330385.0,Mid-Day Market Update: Meadowbrook Insurance Shares Jump On Acquisition News; Crude Oil Drops Over 2%,2014-12-31 12:25:00-05:00,CYTK,negative
330386.0,Cytokinetics Surges Amid Roth Capital Raising Its Price Target,2014-12-31 11:52:00-05:00,CYTK,neutral
330387.0,Cytokinetics Shares Rise 13% Following Roth Capital Raising PT from $13 to $18,2014-12-31 10:27:00-05:00,CYTK,positive
330388.0,Biotech Stocks Make Big Moves In Final Days Of 2014,2014-12-31 09:41:00-05:00,CYTK,neutral
330389.0,13G Filing from Astellas Pharma on Cytokinetics Shows 5.28% Stake,2014-12-29 10:45:00-05:00,CYTK,neutral
330390.0,3 Stocks Blowing Up On Social Media,2014-12-23 11:23:00-05:00,CYTK,neutral
330391.0,Morning Market Movers,2014-12-23 09:54:00-05:00,CYTK,neutral
330392.0,"Tuesday's #PreMarket Movers: NQ Mobile, Cytokinetics, Walgreen And More",2014-12-23 09:23:00-05:00,CYTK,neutral
330393.0,UPDATE: Cytokinetics In Common Stock Purchase Deal with Astellas for ~2.04M Shares at $4.90/Share,2014-12-23 07:37:00-05:00,CYTK,positive
330394.0,"UPDATE: Cytokinetics Will Receive Upfront Payment $30M, Could Get Milestone Payments for Up to $15M",2014-12-23 07:34:00-05:00,CYTK,neutral
330395.0,Shares of Cytokinetics to Resume Trade at 8 a.m. EDT,2014-12-23 07:34:00-05:00,CYTK,positive
330396.0,"Cytokinetics, Astellas Announces Expansion of Deal for Development of CK-2127107 in Spinal Muscular Atrophy, Other Neuromuscular Indications",2014-12-23 07:31:00-05:00,CYTK,neutral
330397.0,Shares of Cytokinetics Halted News Pending,2014-12-23 07:25:00-05:00,CYTK,positive
330398.0,Cytokinetics Offers Development Program Update for Omecamtiv Mecarbil: Saw No Clinically Meaningful Differences Between Two Groups,2014-10-27 07:33:00-04:00,CYTK,neutral
330399.0,Cytokinetics Offers Update on Development Program for Tirasemtiv,2014-10-20 07:33:00-04:00,CYTK,neutral
330400.0,Cytokinetics Provides Update for CK-2127107 ,2014-10-13 07:55:00-04:00,CYTK,neutral
330401.0,Lands' End Jumps On Strong Quarterly Earnings; GT Advanced Technologies Shares Slide,2014-09-10 15:29:00-04:00,CYTK,positive
330402.0,Markets Open Higher; VeriFone Profit Tops Street View,2014-09-04 11:31:00-04:00,CYTK,positive
330403.0,MLV & Co. Sees Good Things Ahead For Cytokinetics,2014-09-02 08:47:00-04:00,CYTK,positive
330404.0,Lansdowne Increases Stake in Cytokinetics From 6.34% to 7.7%,2014-07-10 14:27:00-04:00,CYTK,neutral
330405.0,Cytokinetics Reports Added Results Related to Tirasemtiv from Pre-Specified Subgroup Analyses of BENEFIT-ALS,2014-07-10 07:31:00-04:00,CYTK,neutral
330406.0,Cytokinetics Announces Further Results from BENEFIT-ALS ,2014-06-02 07:38:00-04:00,CYTK,neutral
330407.0,Cytokinetics Offers Further Results from BENEFIT-ALS Related to Effects Following Withdrawal of Tirasemtiv,2014-06-02 07:38:00-04:00,CYTK,neutral
330408.0,Cytokinetics Offers Further Results from BENEFIT-ALS Related to Effects Following Withdrawal of Tirasemtiv,2014-06-02 07:38:00-04:00,CYTK,neutral
330409.0,Cytokinetics Reports Additional BENEFIT-ALS Data to be Presented at Joint Congress of European Neurology  ,2014-05-27 07:36:00-04:00,CYTK,neutral
330410.0,"Cytokinetics, Incorporated Reports Q1 EPS of $(0.27) vs $(0.34) Est; Revenue of $8.0M vs $7.69M Est",2014-05-06 16:35:00-04:00,CYTK,neutral
330411.0,"MLV & Co. Downgrades Cytokinetics, Incorporated to Hold, Lowers PT to $5.00",2014-04-25 15:51:00-04:00,CYTK,negative
330412.0,"Piper Jaffray Downgrades Cytokinetics, Incorporated to Neutral, Lowers PT to $7.00",2014-04-25 10:20:00-04:00,CYTK,negative
330413.0,Stocks Hitting 52-Week Lows,2014-04-25 10:14:00-04:00,CYTK,negative
330414.0,Cytokinetics Shares Fall 68% on Failed BENEFIT-ALS Trial Result ,2014-04-25 08:03:00-04:00,CYTK,negative
330415.0,PREVIEW: CYTOKINETICS to Resume Trading at 8:00 AM ET,2014-04-25 07:44:00-04:00,CYTK,neutral
330416.0,"UPDATE: Cytokinetics Reports Top-Line Results from BENEFIT-ALS Showed Did Not Reach Primary Efficacy Endpoint, Mixed Effects on Secondary Endpoints",2014-04-25 07:33:00-04:00,CYTK,neutral
330417.0,"Cytokinetics Reports Top-Line Results from BENEFIT-ALS Showed Did Not Reach Primary Efficacy Endpoint, Mixed Effects on Secondary Endpoints",2014-04-25 07:32:00-04:00,CYTK,neutral
330418.0,Cytokinetics Shares Halted News Pending,2014-04-25 07:26:00-04:00,CYTK,positive
330419.0,Cytokinetics Move Higher; May be Attributed to Positive Newsletter Mention,2014-04-21 09:43:00-04:00,CYTK,positive
330420.0,Mid-Afternoon Market Update: Markets Post a Large Rally as Intuitive Surgical Shares Remain Down,2014-04-09 15:54:00-04:00,CYTK,positive
330421.0,Mid-Day Market Update: Alcoa Surges On Upbeat Earnings; Intuitive Surgical Shares Slip,2014-04-09 13:06:00-04:00,CYTK,positive
330422.0,13G Filing from SAC Capital on Cytokinetics Shows 5.5% Stake,2014-04-07 17:02:00-04:00,CYTK,neutral
330423.0,Cyotkinetics Reports Opening of Enrollment for Expansion of COSMIC-HF,2014-03-28 07:31:00-04:00,CYTK,neutral
330424.0,Cytokinetics Begins Multi-Dose Phase I Clinical Trial of CK-2127107,2014-03-27 07:33:00-04:00,CYTK,neutral
330425.0,"Roth Capital Reiterates Buy on Cytokinetics, Incorporated, Announces $25.00 PT",2014-03-05 07:32:00-05:00,CYTK,neutral
330426.0,Cytokinetics Prices $35M in Shares at $8/Share,2014-02-20 08:57:00-05:00,CYTK,positive
330427.0,This Week's Sector Gainers And Losers,2014-02-13 11:38:00-05:00,CYTK,negative
330428.0,Cytokinetics Expecting Added CK-2127107 Phase I Studies This Year,2014-02-06 16:46:00-05:00,CYTK,neutral
330429.0,"Cytokinetics, Incorporated Reports Q4 EPS of $0.21 vs $(0.08) Est; Revenue of $24.30M vs $19.14M Est",2014-02-06 16:46:00-05:00,CYTK,neutral
330430.0,"Cytokinetics Offers Update on Program for Omecamtiv Mercarbil, Says Size of Expansion Phase Boosted",2014-01-13 07:35:00-05:00,CYTK,positive
330431.0,"Cytokinetics Issues Results from First-Time-In-Humans Trial, Says CK-2127107 Appears Well Tolerated",2013-12-10 07:33:00-05:00,CYTK,positive
330432.0,Cytokinetics Presents Update on BENEFIT-ALS at International Symposium on ALS/MND ,2013-12-08 10:37:00-05:00,CYTK,neutral
330433.0,Cytokinetics Files $150M Mixed Securities Shelf,2013-11-06 15:46:00-05:00,CYTK,positive
330434.0,"Cytokinetics, Incorporated Sees FY2013 Sales $40.0M-42.0M vs $30.80M Est",2013-10-30 16:15:00-04:00,CYTK,neutral
330435.0,"Cytokinetics, Incorporated Reports Q3 EPS of $(0.43) vs $(0.10) Est; Revenue of $12.60M vs $16.96M Est",2013-10-30 16:14:00-04:00,CYTK,neutral
330436.0,"Cytokinetics Shares Holding Over $6.75 Level, Up 8+% Today; Needham Earlier Suggested Market Misread Co./Amgen's Data on Omecamtiv, Called Results 'More Than Positive Enough'",2013-10-11 11:23:00-04:00,CYTK,positive
330437.0,"Cytokinetics Reports Added Safety, Pharmacodynamic Results from ATOMIC-AHF Study",2013-09-23 16:35:00-04:00,CYTK,positive
330438.0,Hearing Leerink Defending Cytokinetics,2013-09-03 11:00:00-04:00,CYTK,neutral
330439.0,Morning Market Losers ,2013-09-03 09:57:00-04:00,CYTK,negative
330440.0,"Leerink Swann's Schwartz Believes Cytokinetics, Amgen Data Could Warrant More Phase III Testing",2013-09-03 08:15:00-04:00,CYTK,neutral
330441.0,Benzinga's Top Pre-Market Losers,2013-09-03 08:11:00-04:00,CYTK,negative
330442.0,Cytokinetics Shares Fall 33% in Pre-Market on Failed Phase 2 ATOMIC-AHF Study,2013-09-03 07:10:00-04:00,CYTK,negative
330443.0,"Amgen, Cytokinetics Announce Phase 2 ATOMIC-AHF Study Of Omecamtiv Mecarbil Did Not Meet Primary Endpoint",2013-09-03 05:55:00-04:00,CYTK,neutral
330444.0,"Cytokinetics, Incorporated Reports Q2 EPS of $(0.58) vs $(0.54) Est; Revenue of $1.0M vs $3.20M Est",2013-07-31 16:19:00-04:00,CYTK,neutral
330445.0,"Leerink Swann's Schwartz Believes Update on Cytokinetics ALS Trial Removes Overhang, Reiterates Outperform",2013-07-23 11:59:00-04:00,CYTK,neutral
330446.0,Cytokinetics Shares to Resume Trade at 8AM EDT,2013-07-23 07:39:00-04:00,CYTK,positive
330447.0,"Cytokinetics Offers Update, Revised Guidance for BENEFIT-ALS, Sees Patient Enrollment Concluded in 2013, Results in Early 2014",2013-07-23 07:34:00-04:00,CYTK,neutral
330448.0,Cytokinetics Halted with News Pending,2013-07-23 07:26:00-04:00,CYTK,neutral
330449.0,"Leerink Swann Initiates Coverage on Cytokinetics, Incorporated at Outperform, Announces $20.00 PT",2013-07-17 09:15:00-04:00,CYTK,neutral
330450.0,Morning Market Losers ,2013-07-08 10:10:00-04:00,CYTK,negative
330451.0,Cytokinetics Resumes Trading Down 5%,2013-07-08 08:02:00-04:00,CYTK,neutral
330452.0,Cytokinetics Shares to Resume Trade at 8AM EDT,2013-07-08 07:35:00-04:00,CYTK,positive
330453.0,"UPDATE: Cytokinetics Reports Programming Error in Data Capture, Says No Placebo Patients Got Incorrect Treatment, DSMB Reported No Concerns on Patient Safety",2013-07-08 07:35:00-04:00,CYTK,negative
330454.0,"UPDATE: Cytokinetics Halted News Disseminated: Issues Update on BENEFIT-ALS, Says 58 Patients Received Placebo Instead of Drug",2013-07-08 07:32:00-04:00,CYTK,neutral
330455.0,Cytokinetics Halted News Disseminated: Issues Update on BENEFIT-ALS,2013-07-08 07:31:00-04:00,CYTK,neutral
330456.0,Canaccord Genuity Reiterates Buy on Cytokinetics on CK357 Potential,2013-06-26 11:07:00-04:00,CYTK,neutral
330457.0,"Mid-Morning Market Update: Markets Open Higher, Walgreen Profit Misses Estimates",2013-06-25 10:33:00-04:00,CYTK,positive
330458.0,"13D Filing from Amgen on Cytokinetics Shows Raised 7.58% Stake, Had Shown 2.34% as of Feb. 29th, 2012",2013-06-18 17:28:00-04:00,CYTK,neutral
330459.0,"Market Wrap for Tuesday, June 18: Stocks Rally Ahead of Fed Statement ",2013-06-18 16:22:00-04:00,CYTK,neutral
330460.0,Afternoon Market Gainers,2013-06-18 12:35:00-04:00,CYTK,neutral
330461.0,Cytokinetics Announces Results From ATOMIC-AHF Will Be Presented At Late Breaking Clinical Trials Session At The European Society Of Cardiology Congress 2013,2013-06-18 08:40:00-04:00,CYTK,neutral
330462.0,Afternoon Market Gainers ,2013-06-12 13:50:00-04:00,CYTK,neutral
330463.0,"Cytokinetics Shares Resume Trade, Now Up 18%",2013-06-12 08:00:00-04:00,CYTK,positive
330464.0,Shares of Cytokinetics to Resume Trade at 8AM EDT,2013-06-12 07:36:00-04:00,CYTK,positive
330465.0,UPDATE: Cytokinetics Will Receive  $25 Million  Plus Potential Milestone Payments and Royalties,2013-06-12 07:32:00-04:00,CYTK,neutral
330466.0,"Amgen, Cytokinetics Announce Expansion of License for Omecamtiv Mecarbil, Will Receive $25M Plus Potential Milestone, Cytokinetics Will Also Get Possible Royalties",2013-06-12 07:31:00-04:00,CYTK,neutral
330467.0,Cytokinetics Halted News Pending,2013-06-12 07:26:00-04:00,CYTK,neutral
330468.0,"Cytokinetics, Incorporated Reports Q1 EPS of $(0.09), Inline; Revenue of $821.0K vs $680.0K Est",2013-04-30 16:16:00-04:00,CYTK,neutral
330469.0,"UPDATE: Piper Jaffray Initiates Coverage on Cytokinetics with Overweight Rating, $4 PT",2013-01-04 10:15:00-05:00,CYTK,negative
330470.0,"Piper Jaffray Initiates Coverage on Cytokinetics, Incorporated at Overweight, Announces $4.00 PT",2013-01-04 07:14:00-05:00,CYTK,negative
330471.0,Cytokinetics to Transfer Listing from NASDAQ Global Market to NASDAQ Capital Market,2012-12-18 16:04:00-05:00,CYTK,neutral
330472.0,Cytokinetics Opens Third and Final Cohort in ATMOIC-AHF,2012-11-29 07:37:00-05:00,CYTK,neutral
330473.0,UPDATE: Dawson James Initiates Cytokinetics at Market Outperform on Competitive Positioning  ,2012-11-27 12:02:00-05:00,CYTK,positive
330474.0,"Dawson James Initiates Coverage Cytokinetics at Market Outperform, Announces PT of $2.00",2012-11-27 06:40:00-05:00,CYTK,neutral
330475.0,Cytokinetics Offers Results from Phase IIA Trial of Tirasemtiv for Myasthenia Gravis,2012-11-26 07:45:00-05:00,CYTK,neutral
330476.0,Cytokinetics Spikes Higher; Traders Attributing to Positive Article,2012-11-14 11:18:00-05:00,CYTK,positive
330477.0,Cytokinetics Moves Higher on Article Regarding ALS Treatment,2012-11-14 11:12:00-05:00,CYTK,neutral
330478.0,Cytokinetics Reports Q3 EPS $-0.07 vs $-0.11 Est; Revenues $1.7M vs $1.25M Est,2012-10-30 16:24:00-04:00,CYTK,neutral
330479.0,Benzinga's Top Initiations,2012-08-01 10:40:00-04:00,CYTK,positive
330480.0,UPDATE: Rodman & Renshaw Maintains Outperform on Cytokinetics; $2 PT,2012-07-31 09:30:00-04:00,CYTK,neutral
330481.0,Cytokinetics Announces Heart Failure Program Update  ,2012-07-26 07:30:00-04:00,CYTK,negative
330482.0,Benzinga's Top Initiations,2012-07-02 07:35:00-04:00,CYTK,positive
330483.0,"Cytokinetics, Incorporated Announces $60 Million Financing  ",2012-06-20 09:29:00-04:00,CYTK,neutral
330484.0,Cytokinetics Announces Proposed Public Offerings of Common Stock and Warrants and Series B Convertible Preferred Stock and Warrants  ,2012-06-19 16:23:00-04:00,CYTK,neutral
330485.0,Cytokinetics Receives NASDAQ Notice of Minimum Bid Price Non-Compliance  ,2012-06-19 16:01:00-04:00,CYTK,neutral
330486.0,Cytokinetics Announces Opening of Second Cohort in Phase IIb Clinical Trial of Intravenous Omecamtiv Mecarbil in Patients With Acute Heart Failure  ,2012-05-24 07:30:00-04:00,CYTK,negative
330487.0,Cytokinetics Announces Encouraging Results From Two Phase II Clinical Trials Evaluating CK-2017357 in Patients With Amyotrophic Lateral Sclerosis  ,2012-04-25 16:31:00-04:00,CYTK,positive
330488.0,Cytokinetics Announces CK-2017357 Receives Fast Track Designation From the FDA for the Potential Treatment of Amyotrophic Lateral Sclerosis  ,2012-04-19 07:34:00-04:00,CYTK,neutral
330489.0,"UPDATE: MLV Initiates Cytokinetics with Buy, $4 PT ",2012-04-12 12:36:00-04:00,CYTK,neutral
330490.0,Cytokinetics Announces Changes to Its Board of Directors  ,2012-03-07 16:00:00-05:00,CYTK,neutral
330491.0,Cytokinetics Announces That the European Medicines Agency Has Granted CK-2017357 Orphan Medicinal Product Designation for the Treatment of Amyotrophic Lateral Sclerosis  ,2012-03-06 07:32:00-05:00,CYTK,positive
330492.0,Cytokinetics Announces Initiation of Phase I Clinical Trial of Oral Formulations of Omecamtiv Mecarbil in Healthy Volunteers  ,2012-02-21 07:34:00-05:00,CYTK,positive
330493.0,Cytokinetics Announces Positive Results From Phase II Clinical,2011-11-30 07:30:00-05:00,CYTK,positive
330494.0,Cytokinetics Announces Opening of Third Phase II Clinical Trial of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis  ,2011-11-29 07:31:00-05:00,CYTK,neutral
330495.0,Cytokinetics to Present Clinical Trial Data Relating to CK-2017357 in Patients With Amyotrophic Lateral Sclerosis  ,2011-11-22 16:00:00-05:00,CYTK,neutral
330496.0,"Rodman & Renshaw Reiterates Cytokinetics Market Outperform, $4 PT",2011-11-01 16:50:00-04:00,CYTK,neutral
330497.0,Cytokinetics Announces Initiation of Second Cohort of Ongoing Phase II Clinical Trial Evaluating CK-2017357 in Patients With ALS  ,2011-11-01 07:30:00-04:00,CYTK,neutral
330498.0,Rodman & Renshaw Maintains Outperform Rating and $4 PT on Cytokinetics ,2011-10-19 06:32:00-04:00,CYTK,neutral
330499.0,Cytokinetics Announces Strategic Restructuring; Cuts 18 Jobs  ,2011-10-18 16:01:00-04:00,CYTK,negative
330500.0,UPDATE: Rodman & Renshaw Initiates Coverage on Cytokinetics at Market Outperform,2011-10-13 07:00:00-04:00,CYTK,neutral
330501.0,"Rodman & Renshaw Initiates Cytokinetics at Market Outperform, $4 PT",2011-10-13 05:54:00-04:00,CYTK,neutral
330502.0,Cytokinetics Announces First Publication on Smooth Muscle Myosin Inhibitors,2011-09-27 07:32:00-04:00,CYTK,negative
330503.0,Cytokinetics Announces Phase I and Phase IIa Clinical Trial Results for Omecamtiv Mecarbil Published in the Journal Lancet ,2011-08-19 08:00:00-04:00,CYTK,neutral
330504.0,Cytokinetics Announces Opening of Next Phase II Clinical Trial of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis  ,2011-06-21 07:35:00-04:00,CYTK,neutral
330505.0,"Cytokinetics Announces Successful Completion of Phase IIA ""Evidence of Effect"" Clinical Trial of CK-2017357",2011-06-02 16:03:00-04:00,CYTK,positive
330506.0,Cytokinetics Announces Opening of Phase IIb Clinical Trial of Intravenous Formulation of Omecamtiv Mecarbil in Patients With Acute Heart Failure  ,2011-04-19 07:43:00-04:00,CYTK,negative
330507.0,Cytokinetics Announces $20 Million Financing ,2011-04-18 08:34:00-04:00,CYTK,neutral
330508.0,Cytokinetics Announces Presentation of Data From a Phase IIa Clinical Trial of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis at the 63rd Annual Meeting of the American Academy of Neurology (CYTK),2011-04-18 08:01:00-04:00,CYTK,neutral
330509.0,Cytokinetics Up 9% (CYTK),2011-04-12 09:59:00-04:00,CYTK,neutral
330510.0,"Top Trade Ideas for Tuesday, April 12",2011-04-11 16:52:00-04:00,CYTK,positive
330511.0,"Cytokinetics Announces Data From Phase IIa ""Evidence of Effect"" Clinical Trial of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis to Be Presented at the 63rd Annual Meeting of the American Academy of Neurology  ",2011-04-11 07:55:00-04:00,CYTK,neutral
330512.0,"Cytokinetics Announces Opening of a Phase IIa ""Evidence of Effect"" Clinical Trial",2011-01-04 07:51:00-05:00,CYTK,neutral
330513.0,"Afternoon Market Update (LCC, UAL, LFL, GOL, RY, CYTK)",2010-12-13 12:13:00-05:00,CYTK,neutral
330514.0,Cytokinetics Setting Up Well Technically,2010-12-08 10:26:00-05:00,CYTK,positive
330515.0,How Best To Play The Relief Rally In The Stock Market ,2010-05-11 09:56:00-04:00,CYTK,positive
330516.0,How Will Obama-Care Play Into The Markets And ETFs?,2010-03-21 21:50:00-04:00,CYTK,positive
330517.0,"Benzinga’s Top Pre-Market Gainers (AEO, FACT, ITMN, CYTK)",2010-03-10 08:31:00-05:00,CYTK,positive
330518.0,"Benzinga’s Top Pre- Market Losers (CIEN, LLY, OSIP, PROV, CYTK, AOL, SIGA)",2009-12-10 09:00:00-05:00,CYTK,negative
330519.0,"New 52-Week High (ACS,COMS,GMCR,CYTK,RINO)",2009-09-28 11:20:00-04:00,CYTK,neutral
